GO Therapeutics develops a validated discovery platform that identifies super-clean cancer targets exclusive to tumor cells, enabling the creation of targeted therapies for solid tumors. This approach addresses the challenge of unsuitable targets that hinder the effectiveness of current cancer treatments, such as T-cell bispecific antibodies and CAR-T therapies.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments, such as T-cell bispecific antibodies and CAR-T therapies, are often hindered by the lack of suitable targets that are specific to tumor cells, leading to off-target effects and reduced efficacy in solid tumors. Many existing cancer targets are also found on healthy cells, limiting the potential of advanced therapeutic modalities.
Solution
GO Therapeutics is developing a discovery platform to identify novel cancer targets that are highly specific to tumor cells, enabling the creation of targeted therapies for solid tumors. The platform aims to address the limitations of current cancer treatments by identifying "super-clean" targets that are exclusive to tumor cells, thereby minimizing off-target effects and improving therapeutic efficacy. By focusing on these novel targets, GO Therapeutics seeks to unlock the full potential of advanced therapeutic modalities and develop more effective treatments for a broad spectrum of solid tumor patients. The company is also developing antibodies against these novel targets.
Target Audience
The primary audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for solid tumors, as well as patients with solid tumors who may benefit from more effective and targeted treatment options.
Features
- Discovery platform for identifying novel, super-clean cancer targets
- Focus on targets exclusive to tumor cells to minimize off-target effects
- Aims to improve the efficacy of T-cell bispecific antibodies, ADCs, CAR-T, and immunomodulators
- Developing antibodies against identified targets